BRCA2 and cancer: Consequentially and significantly, the antitumor activity of POLθ inhibition is augmented by anti-PD-1 immunotherapy in a Brca2-deficient mouse model of PDAC, representing a novel therapeutic strategy to sensitize HR-deficient cancers to immunotherapy.